GAST and gastric neuroendocrine tumor, well differentiated, low or intermediate grade: Netazepide, a specific gastrin antagonist with few if any side effects and proven efficacy in the treatment of gastric NETs, has not been tried in the treatment of gastric cancers although gastrin receptors are frequently expressed.